Core Insights - Annovis Bio Inc. is participating in the AD/PD™ 2025 conference from April 1-5 in Vienna, focusing on transformative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's [1][2]. Company Overview - Annovis Bio is a late-stage clinical drug platform company headquartered in Malvern, Pennsylvania, dedicated to developing innovative therapies aimed at improving patient outcomes in neurodegenerative diseases [4]. Clinical Developments - The company is in late clinical stages for both Alzheimer's and Parkinson's diseases, with upcoming presentations at the conference showcasing data from Phase 3 PD and Phase 2/3 AD studies [2]. - The presentations will cover the cognitive response in early Parkinson's patients and the benefits of the drug buntanetap for APOE4 carriers in Alzheimer's patients [2][3]. Conference Participation - Annovis will present two key studies and participate in a forum discussion on novel approaches to accelerate the development of biomarkers and therapies related to Parkinson's disease and other neurological disorders [3]. - Specific presentation details include: - "BUNTANETAP IMPROVES EARLY PARKINSON'S PATIENTS' COGNITION AND MOTOR FUNCTIONS IN A PHASE 3 STUDY" [3]. - "APOE4 AND BUNTANETAP IN PHASE II/III ALZHEIMER'S PATIENTS" [3]. Leadership Engagement - Maria Maccecchini, Ph.D., Founder and CEO, will present on April 1 and April 4, while Cheng Fang, Ph.D., SVP of Research and Development, will present on April 2 [7].
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program